Novel Treatments Targeting Drug-Resistant Prostate Cancer Cells

Summary of the technology

- Novel small molecule carbazole compounds effectively inhibit androgen receptor signaling, overcoming resistance to current prostate cancer treatments.
- Broad efficacy against castration-resistant and enzalutamide-resistant prostate cancer addresses critical unmet needs in advanced disease.
- Potential applications extend beyond prostate cancer to other androgen receptor-positive cancers, including breast, ovarian, and fallopian tube cancers.

Georgetown University

Details of the Technology Offer

OVERVIEW

The technology relates to small molecule androgen receptor inhibitors and methods of using the same for treating prostate cancer. The novel compounds have demonstrated efficacy for disrupting androgen receptor signaling and inducing apoptosis in castration-resistant and enzalutamide-resistant prostate cancer cells. Some in vitro data for the lead carbazole compound, SH-I-125, suggests that it is more effective than the clinically significant androgen receptor inhibitors MDV3100 and ARN-509.

BACKGROUND

Prostate cancer is a significant health concern, ranking as the most common cancer among men in 2019, excluding non-melanoma skin cancer. With an incidence rate of 658 per 100,000 males in 2019, it represents a substantial burden on public health. This high prevalence underscores the importance of ongoing research and innovation in prostate cancer detection, treatment, and management. Advances in these areas are crucial for improving patient outcomes and addressing the challenges posed by this widespread malignancy. Innovations in targeted therapies, diagnostic tools, and treatment strategies are continually being developed to enhance the quality of life for patients and increase survival rates.

Benefit

  • Offers a new approach to treating castration-resistant and drug-resistant prostate cancer through a novel class of small molecule inhibitors.
  • Provides an alternative to current anti-androgens, potentially improving long-term outcomes.
  • Potentially applicable to other androgen receptor-positive cancers.

Market Application

  • Targets castration-resistant and enzalutamide-resistant prostate cancer patients, addressing a significant unmet medical need.
  • Serves as an adjunctive treatment option alongside current anti-androgens or chemotherapy agents to improve outcomes.
  • Provides a foundation for future drug development, with potential applications across different cancers.

Publications

  • Amin, Karishma S., et al. "A Synthetic Small Molecule Carbazole SH-I-125 Degrades Androgen Receptor and Overcomes Castration-Resistance and Enzalutamide-Resistance in Prostate Cancer Cells."Medical Research Archives

10.6 (2022).

  • Banerjee, Partha P., and Shiv Srivastava. "Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment."Handbook of Oncobiology: From Basic to Clinical Sciences

(2023): 1-29.
Granted U.S. Pat. Nos. 10,173,978 and 11,104,646

Related Keywords

  • Medicine, Human Health
  • Cytology, Cancerology, Oncology
  • Medical Research
  • Oncology
  • prostate cancer
  • androgen receptor
  • carbazoles
  • prostatic neoplasms
  • signal transduction

About Georgetown University

Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.

Georgetown University

Never miss an update from Georgetown University

Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide

Georgetown University

Send a request for information
to Georgetown University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support